Quoin Pharmaceuticals, Ltd. — Company profile
Healthcare · Biotechnology · United States
Last price 4.54 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 21.81M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company’s lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
Details
| Name | Quoin Pharmaceuticals, Ltd. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 6 |
| Founded | 2018 |
| Ceo | Michael Myers |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US74907L4095 |
| Cusip | 74907L409 |
| Cik | 0001671502 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Dr. Michael Myers Ph.D. | Co-Founder, Chief Executive Officer and Chairman |
| Denise Carter | Co-Founder, Chief Operating Officer and Director |
| Sally Lawlor | Chief Financial Officer |
Contact
| Address | 42127 Pleasant Forest Court, Ashburn, Virginia 20148-7349, United States |
| Phone | 703 980 4182 |
| Website | https://quoinpharma.com |